1700023I07Rik Inhibitors are distinguished by its focus on a specific molecular target, necessitating a deep understanding of the protein's structure and function within cellular systems. The creation of these inhibitors is rooted in the realm of molecular biology and biochemistry, where the intricate details of the protein's role and interactions within the cell are meticulously studied. These inhibitors are typically small molecules, designed through sophisticated chemical synthesis processes. Their development is a fine balance of achieving specificity and affinity for the target protein, ensuring effective interaction. This process often involves rigorous structure-activity relationship (SAR) studies, where the molecular structures of these compounds are methodically adjusted to improve their interaction with the protein, enhancing their efficacy and selectivity.
The journey of developing 1700023I07Rik Inhibitors is marked by a combination of complex chemical synthesis and detailed biological analysis. The initial phase often involves elucidating the protein's structure, utilizing advanced techniques such as X-ray crystallography, nuclear magnetic resonance (NMR) spectroscopy, and computational modeling. These methods are crucial in identifying potential binding sites on the protein, which are key to designing effective inhibitors. The chemical synthesis of these inhibitors is a multistep process, with each reaction tailored to optimize the yield, purity, and the pharmacokinetic properties of the compounds. Following synthesis, these inhibitors undergo comprehensive in vitro testing to assess their binding affinity, specificity, and overall effectiveness in modulating the activity of the target protein. This evaluation is critical for understanding the molecular basis of the inhibitor-protein interaction and plays a central role in further refining the inhibitors' chemical structure. The development of 1700023I07Rik Inhibitors, thus, represents a sophisticated intersection of chemical engineering and biological understanding, underlining the intricate process involved in creating compounds that can precisely modulate specific protein functions within the complex tapestry of biological systems.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
A broad-spectrum kinase inhibitor, potentially affecting phosphorylation pathways. | ||||||
Sodium Orthovanadate | 13721-39-6 | sc-3540 sc-3540B sc-3540A | 5 g 10 g 50 g | $45.00 $56.00 $183.00 | 142 | |
A phosphatase inhibitor, possibly influencing dephosphorylation processes. | ||||||
Triptolide | 38748-32-2 | sc-200122 sc-200122A | 1 mg 5 mg | $88.00 $200.00 | 13 | |
A transcription factor inhibitor, potentially impacting gene regulation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
An mTOR inhibitor, possibly affecting cell growth and proliferation pathways. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
A proteasome inhibitor, which could influence protein degradation. | ||||||
Nifedipine | 21829-25-4 | sc-3589 sc-3589A | 1 g 5 g | $58.00 $170.00 | 15 | |
A calcium channel blocker, potentially affecting calcium signaling. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A PI3K inhibitor, which might impact PI3K/Akt signaling pathways. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
A PI3K inhibitor, which could affect PI3K/Akt signaling pathways. | ||||||